📉Is elevated #cortisol behind your patient’s hard-to-control #type2diabetes?
Prof. Ralph DeFronzo discusses what populations might be affected, as well as screening and treatment options in the latest #ExpertInsights episode.
📺Watch now: easd-elearning.eu/episode/363/...

Follow @biohackingpathway for more

#LessSocialMediaMoreLife #MisfoldedProteins #ProteinFolding #Type2Diabetes #AlzheimersDisease #MetabolicSyndrome #wellnessatwork #wellnessquotes #physicalwellbeing #Health #Science #MedicalResearch #Disease #LessSocialMediaMoreLife

✅ Provides novel pathology insights for T2D treatment development 🏥New breakthrough on #PancreaticBetaCells & #Type2Diabetes!
🧬 A cutting-edge pseudotime analysis deciphers β cell dynamics in health and T2D, uncovering 3 key cell states (Normal/Obesity-like/T2D-like) and their gene signatures!

Novo Nordisk flags. Courtesy of Novo Nordisk.

Novo Nordisk reported phase 2 results for UBT251 in type 2 diabetes, showing strong HbA1c and weight reduction after 24 weeks. Larger studies will still matter.

jcst2d.com/index.php/ne...

#Type2Diabetes #NovoNordisk #ClinicalTrials

#diabetesbien #normoglucemia #rosyyaneznutricion #diabetes #type1diabetes #type2diabetes #t1d #diabetesawareness #diabetessupport #glucosanormaldrarosy #cgm #continuousglucosemonitoring #bloodsugarcontrol #bloodsugar #controldeglucosa #resistenciaalainsulina #prediabetes #lowcarb #keto

#LiverHealth #GutHealth #UltraProcessedFood #ModernDiet #AutoimmuneDisease #Type2Diabetes #FattyLiver #LeakyGut #HealthyEating #Podcast

#diabetesbien #normoglucemia #rosyyaneznutricion #diabetes #type1diabetes #type2diabetes #t1d #diabetesawareness #diabetessupport #glucosanormaldrarosy #cgm #continuousglucosemonitoring #bloodsugarcontrol #bloodsugar #controldeglucosa #resistenciaalainsulina #prediabetes #lowcarb #keto

image

Unmanaged high blood sugar acts as a slow-moving toxin to your blood vessels and nerves long before major symptoms appear. Choosing to get a routine A1C test can catch insulin resistance during its stealthy early stages.

https://wp.drvinternalmedicine

#drvuslat #houstonhealth #type2diabetes

#diabetesbien #normoglucemia #rosyyaneznutricion #diabetes #type1diabetes #type2diabetes #t1d #diabetesawareness #diabetessupport #glucosanormaldrarosy #cgm #continuousglucosemonitoring #bloodsugarcontrol #diabetestipo1 #normoglycemia #diabetesgestacional #prevenciondiabetes #complicacionesdiabetes

Liver stiffness measurement independently predicts mortality risk in type 2 diabetes Liver stiffness measurement is an independent risk factor for overall mortality in people with type 2 diabetes, even over just 2 years of follow-up.

#MedNews - Liver stiffness measurement is an independent risk factor for overall mortality in people with #Type2Diabetes, even over just 2 years of follow-up.

Full story 👉 buff.ly/QOLSRNp

#T2D #Diabetes

JAMA Cardiology Editor's Note: "Exploring Additional Cardiorenal Outcomes—Beyond the Primary Composite End Point" by Gregg C. Fonarow, MD@1, John J. V. McMurray, MD@2. Published Online: March 28, 2026.

💬 Editor's Note: Dual incretin therapy may improve cardiorenal outcomes when broader endpoints are considered, but robust superiority trials are needed for #Type2Diabetes.

#ACC26 @accintouch.bsky.social

ja.ma/3O6evo0

One Blood Type Appears to Carry a Higher Risk of Type 2 Diabetes People with blood type B may need to be a little more vigilant than their peers about the lifestyle factors associated with diabetes risk.

www.sciencealert.com/one-blood-ty...

#diabetes #type2diabetes #blood #health

Line graphs show mean blood pressure values over time. Graph A: SBP for placebo, the value decreases slightly from approximately text@134.5 to text@132. Graph B: DBP. Both values decrease to approximately text@74.5. Graph C: PP decreases from text@58 to text@57.5.

#Type2Diabetes patients at high cardiovascular risk receiving oral #semaglutide demonstrated early and sustained improvements in glycated hemoglobin, body weight, systolic blood pressure, and lipid profiles vs placebo.

ja.ma/4lVmHUB

Awiqli (Insulin Icodec) 3 ml Pen

FDA approval of Awiqli gives adults with type 2 diabetes the first once-weekly basal insulin option in the U.S., reducing injections from daily to weekly.

jcst2d.com/index.php/ne...

#Type2Diabetes #DiabetesCare #Insulin

🧬Molecule of the Moment | 🧠New research shows #Metformin doesn’t just act in the liver, it directly affects the #brain, regulating glucose via hypothalamic neurons (#Rap1/#SF1 pathway)

🧪MedChemExpress provides Metformin for research use only: medchemexpress.com/metformin.html
#Type2Diabetes

Loving my Blood Glucose Sensor!
youtu.be/nuoidFscMg0
#youtube #diabetes #type2diabetes

speaking of--

Our #DiabetesInColor series features artist activations focused on creative activities that support people living w/or at risk for #Type2Diabetes in DC

join us on 3/28 @ Turkey Thicket Rec Center, 11am-1:30pm for sound healing & water aerobics

www.eventbrite.com/e/artivists-...

📣 Our March newsletter is here!

Find out more about global experts publishing a landmark #type2diabetes update, a research participant who has gained control of their condition, an upcoming global research event in sub-Saharan #Africa & more!

🔗 www.linkedin.com/pulse/diabet...

Line graphs show mean blood pressure values over time. The SBP graph shows placebo decreasing slightly while oral semaglutide increases. The DBP graph shows both decreasing, with oral semaglutide slightly lower. The PP graph shows placebo steady, oral semaglutide increasing.

#Type2Diabetes patients at high cardiovascular risk receiving oral #semaglutide demonstrated early and sustained improvements in glycated hemoglobin, body weight, systolic blood pressure, and lipid profiles vs placebo.

ja.ma/40RRRmk

GLP-1s Linked to Reduced Anxiety, Suicidality, With Mark Taylor, MD | HCPLive New study finds GLP-1 RAs are associated with lower anxiety, suicidality, and sick leave in patients with diabetes and mental illness.

Real-world data shows #GLP-1 receptor agonists, especially semaglutide, may reduce anxiety, suicidality, and psychiatric-related sick leave in patients with #Type2diabetes patients. #MentalHealth

Eli Lilly Logo

Retatrutide’s first Phase 3 diabetes results are drawing attention for strong A1C and weight loss, plus what clinicians see as real relevance for type 2 diabetes care.

jcst2d.com/index.php/ne...

#Type2Diabetes #Retatrutide #ObesityCare

Impact of canagliflozin on the cardiorenal effects of dietary sodium intake in type 2 diabetes: a post hoc analysis of the CREDENCE trial - Diabetologia Aims/hypothesis Sodium–glucose cotransporter 2 (SGLT2) inhibitors provide cardiovascular and renal protection in type 2 diabetes and chronic kidney disease (CKD). Although both excess and restricted s...

Reduced sodium intake is associated with a higher risk of heart failure and cardiovascular death but this excess risk is attenuated by canagliflozin #type2diabetes #heartfailure #SGLT2inhibitors link.springer.com/article/10.1...

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats,...

A natural compound, palmatine, showed promise in easing fatty liver and inflammation in a preclinical diabetes study 🧬🩺
www.news-medical.net/news/2026032... #Palmatine #Type2Diabetes #FattyLiver

Off for my first eye screening tomorrow. Not worried, but a bit nervous… #T2D #Type2Diabetes #Diabetes

Living with Type 2 diabetes is a journey of daily choices, patience, and care. Nutrition, movement, and support all matter. 

www.placidway.com/article/6811/Type-2-Diab...

#Type2Diabetes #PatientSupport #HopeAndHealing

How long should you take GLP-1 drugs? Study links longer use to lower heart risk Continuous use of GLP-1 receptor agonists in adults with type 2 diabetes was associated with a lower risk of major cardiovascular events compared with sulfonylureas, with benefits increasing over time...

How long should you stay on GLP-1 meds? 🩺 New study finds that longer, uninterrupted use slashes heart risk - but even brief breaks may erase key benefits for people with type 2 diabetes. www.news-medical.net/news/2026031... #GLP1 #HeartHealth #Type2Diabetes @bmjmedicine.bsky.social

mHealth Intervention to Promote Nonexercise Physical Activity in Patients With Type 2 Diabetes: Secondary Analysis and Implementation Study Background: Physical activity (PA) has an important role in the prevention and treatment of type 2 diabetes (T2D). Interventions with mobile-based technology (mobile health [mHealth]) seem promising in PA promotion, but their behavioral framework is often vague, and the implementation is seldom reported. Objective: This paper examines perceived behavior change needs and implementation of an mHealth approach in increasing nonexercise PA in patients with T2D. Methods: A 3-arm mHealth intervention was conducted in primary care. Information on perceived behavior change needs was collected with a modified capability, opportunity, motivation—behavior (COM-B) questionnaire before the intervention from a separate sample of patients with T2D (n=25) and at the intervention baseline (n=119). Implementation evaluation focused on the fidelity and acceptability of the main arm of the intervention (n=39), which included 24-hour accelerometer use, a smartphone app with personal feedback, a PA leaflet, a YouTube video on walking, and individual counseling with 3 face-to-face sessions and 4 telephone contacts. Data on fidelity were accumulated during the intervention through counseling cards and cloud computing. Data on acceptability were collected with a questionnaire at the end of the intervention (Likert scale from 1 to 5). Data analysis was mainly descriptive. Results: The participants’ responses revealed 3 items in capability and 2 in motivation, which stood out as perceived behavior change needs. Moreover, the main intervention arm showed good fidelity (eg, face-to-face sessions: 112/117, 96% and telephone contacts completed: 145/156, 93%; mean weekly accelerometer use 54%; ranging from 80% to 17% during the intervention) and acceptability (mean score ranging from 3.8 to 4.8), although some challenges were also experienced, especially in cloud-computed feedback and accelerometer-app use. Conclusions: The findings on behavior change needs call for additional research since no comparable studies were found. In addition, the explanatory value of the COM-B model and the psychometric properties of the COM-B questionnaire deserve further attention. The main intervention arm seemed applicable to clinical practice. However, the challenges discovered underscore the importance of pretesting technology-based approaches in patients with T2D. Trial Registration: ClinicalTrials.gov NCT04587414; https://clinicaltrials.gov/study/NCT04587414

JMIR Formative Res: mHealth Intervention to Promote Nonexercise Physical Activity in Patients With Type 2 Diabetes: Secondary Analysis and Implementation Study #mHealth #Type2Diabetes #PhysicalActivity #HealthTech #DiabetesCare

#EliLilly has positive phase 3 results for its #tripleagonist #retatrutide in #type2diabetes (T2D) to go with its earlier encouraging data as a #weightloss therapy.

buff.ly/uQvFKBe

Stopping GLP-1 drugs can quickly erase cardiovascular benefits – BioNews Central Stopping or interrupting GLP-1 drugs for six months or more in type 2 diabetes patients raises the risk of major cardiovascular events by up to 22%, undoing previous benefits. ...

Stopping or interrupting #GLP1Drugs for six months or more in #Type2Diabetes patients raises the risk of major #CardiovascularEvents by up to 22%, undoing previous benefits. 
#GLP1 #GLP1Medications #CardiovascularRisk

Why nurses are key to bridging the type 2 diabetes care gap Learn why nurses are central to type 2 diabetes prevention and management, and understand the barriers they face to delivering this care.

Why nurses are key to bridging the type 2 diabetes care gap

Nurses are central to type 2 diabetes prevention and management, but they face barriers to delivering this care.
#nurse #nurses #nursing #health #healthcare #diabetes #endocrinology #type2diabetes

www.nursingtimes.net/diabetes/why...